SFA
ACXP icon

Semmax Financial Advisors’s Acurx Pharmaceuticals ACXP Stock Holding History

Semmax Financial Advisors’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$684 Sell
8
-274
-97% -$2.21K ﹤0.01% 376
2025
Q1 		$2.03K Sell
282
-77
-21% -$1.04K ﹤0.01% 326
2024
Q4 		$5.43K Buy
359
+65
+22% +$1.96K ﹤0.01% 254
2024
Q3 		$10.9K Hold
294
– – ﹤0.01% 213
2024
Q2 		$11.2K Hold
294
– – ﹤0.01% 230
2024
Q1 		$12.3K Hold
294
– – ﹤0.01% 201
2023
Q4 		$16.5K Hold
294
– – 0.01% 194
2023
Q3 		$20.6K Buy
+294
New +$11.2K 0.01% 164
2022
Q4 		$24K Hold
294
– – 0.01% 145
2022
Q3 		$17K Hold
294
– – 0.01% 149
2022
Q2 		$28K Buy
294
+231
+367% +$15.6K 0.01% 131
2022
Q1 		$4K Hold
63
– – ﹤0.01% 218
2021
Q4 		$5K Hold
63
– – ﹤0.01% 205
2021
Q3 		$6K Buy
+63
New +$6.5K ﹤0.01% 189

Other funds holding ACXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OBGC
O'Brien Greene & Co Media, Pennsylvania $353M AUM 30.94% 1-Year Est. Return

Semmax Financial Advisors's ACXP Position: Q2 2025 in Review

Semmax Financial Advisors reduced its Acurx Pharmaceuticals (ACXP) stake by 97% in Q2 2025, selling an estimated $2.21K and leaving 8 shares worth $684. The position accounts for ﹤0.01% of the portfolio, ranked #376.

Semmax Financial Advisors first reported a position in ACXP in Q3 2021 and has held it in 14 quarters since. The position peaked at $28K in Q2 2022. 32 funds tracked by Wall St. Rank hold ACXP as of Q2 2025.

  • Semmax Financial Advisors held 8 shares of Acurx Pharmaceuticals worth $684 as of Q2 2025.
  • Semmax Financial Advisors sold 274 Acurx Pharmaceuticals shares in Q2 2025, an estimated $2.21K.
  • Acurx Pharmaceuticals made up ﹤0.01% of Semmax Financial Advisors's portfolio in Q2 2025, its #376 holding.
  • Semmax Financial Advisors first reported a position in Acurx Pharmaceuticals in Q3 2021 and has held it in 14 quarters since.
  • Semmax Financial Advisors's Acurx Pharmaceuticals position peaked at $28K in Q2 2022.
  • 32 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2025.

Based on Semmax Financial Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.